Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug. http://feeds.foxnews.com/~r/foxnews/health/~3/l4sQPQ6SA90/
Read More
i think your blog very informative, thanks for sharing.
ReplyDelete